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Abstract
Background: Methicillin resistance in Staphylococcus aureus is conferred by the mecA-encoded
penicillin-binding protein PBP2a. Additional genomic factors are also known to influence resistance
levels in strain specific ways, although little is known about their contribution to resistance
phenotypes in clinical isolates. Here we searched for novel proteins binding to the mec operator, in
an attempt to identify new factor(s) controlling methicillin resistance phenotypes.
Results: Analysis of proteins binding to a DNA fragment containing the mec operator region
identified a novel, putative helix-turn-helix DNA-binding protein, SA1665. Nonpolar deletion of
SA1665, in heterogeneously methicillin resistant S. aureus (MRSA) of different genetic backgrounds,
increased methicillin resistance levels in a strain dependent manner. This phenotype could be fully
complemented by reintroducing SA1665 in trans. Northern and Western blot analyses, however,
revealed that SA1665 had no visible influence on mecA transcription or amounts of PBP2a
produced.
Conclusion: SA1665 is a new chromosomal factor which influences methicillin resistance in MRSA.
Although SA1665 bound to the mecA promoter region, it had no apparent influence on mecA
transcription or translation, suggesting that this predicted DNA-binding protein modulates resistance
indirectly, most likely through the control of other genomic factors which contribute to resistance.
Background
Methicillin resistant S. aureus (MRSA) are an ever
increasing threat, both in clinical settings and more
recently as an emerging community acquired pathogen.
Their invasiveness and pathogenesis relies on a variable
arsenal of virulence factors, paired with resistance to
virtually all b-lactams and their derivatives. Their ability
to rapidly generate resistance to other unrelated classes
of antibiotics, or to take up additional resistance
determinants, severely hampers therapy and eradication.
In S. aureus, methicillin resistance is conferred by an
acquired, b-lactam-insensitive penicillin-binding protein
(PBP), PBP2a [1-4]. PBP2a is encoded by mecA,w h i c hi s
divergently transcribed from its cognate regulators,
mecR1 (sensor/signal transducer) and mecI (repressor).
If mecR1-mecI are absent or truncated, transcriptional
control of mecA is taken over by the structurally similar
blaZ (penicillinase) regulatory elements blaR1/blaI,i f
present. In the absence of both regulatory loci, mecA is
constitutively transcribed [5, 6]. In the presence of
b-lactams, the transmembrane sensor/signal transducers
BlaR1/MecR1, undergo a conformational change, fol-
lowed by autoproteolytic cleavage of the n-terminal
cytoplasmic domain, leading to the activation of the
cytoplasmic peptidase and subsequent dissociation of
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However, the signal transduction cascade of this reg-
ulatory system has still not been completely elucidated.
Oxacillin resistance levels conferred by mecA are strain
specific and can vary greatly, with oxacillin minimal
inhibitory concentrations (MICs) of different strains
ranging from phenotypically susceptible levels, as low as
1 μg/ml up to extremely high values of > 500 μg/ml.
Methicillin resistance is also generally expressed hetero-
geneously. Heterogeneously resistant MRSA, when
exposed to b-lactam antibiotics, segregate highly resis-
tant subpopulations, which are much more resistant
than the majority of the cells [10]. The frequency of
highly resistant subclones generated is often well above
the spontaneous mutation frequency, and once selected
high level resistance often remains stable, even in the
absence of selective pressure. There is currently no
satisfactory genetic model which explains how these
higher resistance levels are triggered or selected and
exactly what factors are functionally responsible for the
increased resistance in clinical isolates. Methicillin
resistance levels are known to not directly correlate
with mecA transcription or levels of PBP2a produced [11,
12]. However, resistance levels can be manipulated by
environmental conditions, such as temperature, pH,
osmolarity, and medium composition [13, 14].
It has been shown experimentally, that in addition to
mecA, methicillin resistance depends on the correct
interplay of a multitude of genomic factors, termed
fem/aux factors, including genes involved in peptidogly-
can precursor formation, composition and turnover;
teichoic acid synthesis; and genes of unknown or poorly
characterised functions [15-18]. In addition to structural
genes, many regulatory loci have also been shown to
influence resistance levels, including global regulators of
virulence factor production such as the quorum sensing
agr system, the staphylococcal accessory regulator SarA
and the alternate sigma factor s
B [19, 20]; regulators of
metabolism, such as the catabolite control protein A
(CcpA) [21]; and the VraSR two-component sensor
transducer, which induces thec e l lw a l ls t r e s ss t i m u l o n
in response to cell wall active antibiotic challenge [22].
The vast MIC differences between MRSA strains, the
population heterogeneity within single strains and the
dependence of resistance levels on external factors are
reflected in these many structural genes and global
regulators, which can influence resistance levels.
While typically considered nosocomial pathogens, new
faster growing and apparently more virulent MRSA have
begun spreading in the community. Interestingly, these
emerging strains often express very low methicillin
resistance, e.g. the MRSA clone spreading amongst
intravenous drug users in the Zurich area, which has an
in vitro doubling time of 25 min, but oxacillin MICs of
only 0.5 to 4 μg/ml [23]. This particular clone's low-level
resistance is partially due to a promoter mutation,
leading to tight repression of mecA, but resistance levels
appear to be mainly restricted by unknown factors
within its genomic background [12].
To identify potential factors involved in mecA regulation
or methicillin resistance levels in such an extremely low
level resistant MRSA, we performed DNA-binding
protein purification assays, using the mecA operator
region as bait. A novel, uncharacterized protein, SA1665,
w a sf o u n dt ob i n dt ot h i sD N Af r a g m e n t ,a n ds h o w nt o
increase methicillin resistance levels when deleted.
Results
Identification of SA1665
MRSA strain CHE482 is the type strain for the so-called
"drug clone" spreading amongst intravenous drug users
in the Zurich area [12, 23]. This strain carries mecA and
expresses PBP2a, but appears phenotypically methicillin
susceptible by conventional phenotypic tests. However,
like most other low-level resistant MRSA, it can segregate
a small proportion of higher resistant subclones in the
presence of b-lactams. We hypothesized that regulation
of methicillin resistance in such low-level resistant clonal
lineages may differ qualitatively from classical hetero-
geneously- or highly-resistant MRSA.
A DNA-binding protein purification assay was performed
to identify new potential factors involved in the regulation
of mecA/PBP2a. The mecA/mecR1 intergenic DNA region,
including the 5' 9 bp of mecR1 and the first 52 bp of mecA,
was used as bait against crude protein extract from strain
CHE482. Proteins binding to this DNA fragment were
analysed by SDS-PAGE. Even though CHE482 contained
BlaI, which is known to bind to the mec operator, this band
could not be identified on gels due to co-migrating, non-
specific bands the same size as BlaI (14.9 KDa) that bound
to both the DNA-coated and uncoated control beads. The
most prominent protein band of ~16–20 kDa, isolated
from DNA-labelled but not from control beads, was
identified as the hypothetical protein SA1665 (N315
genome annotation [BA000018]) (Figure 1A). SA1665
encodes a predicted 17-kDa protein with an n-terminal
helix-turn-helix (HTH) motif characteristic of DNA-binding
transcriptional regulators. The amino acid sequence of
SA1665 showed 100% identity amongst S. aureus database
sequences and 97–98% identity amongst other staphylo-
cocci, including S. haemolyticus, S. epidermidis and
S. saprophyticus, indicating that SA1665 is highly conserved.
Conversely, there were no orfs highly similar to SA1665
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sequences found in Bacillus licheniformis DSM13 and
Desulfitobacterium hafniense Y51, which shared only 64%
and 59% similarity, respectively.
Electro mobility shift assays (EMSA)
EMSA was used to confirm binding of SA1665 to the mec
operator region. Crude protein extracts of E. coli strain
BL21, carrying the empty plasmid (pET28nHis6)o r
pME20 (pET28nHis6-SA1665) which expressed nHis6-
SA1665 upon induction with IPTG, were incubated with
the 161-bp biotinylated-DNA fragment previously used
as bait in the DNA-binding protein assay. A band shift
was observed with extracts from the strain expressing
recombinant nHis6-SA1665 but not from the control
strain carrying the empty plasmid. Several bands resulted
from the shift, which is most likely due to protein
oligomerisation (Figure 2A). The specificity of the gel
shift was also demonstrated by the addition of increasing
concentrations of purified nHis6-SA1665 protein to the
biotinylated-DNA fragment (Figure 2B). Band-shift of
the biotinylated DNA was inhibited in the presence of
specific competitor DNA but not by the presence of the
non-specific competitor DNA, confirming that nHis6-
SA1665 had a specific binding affinity for the 161-bp
DNA fragment.
Effect of SA1665 deletion on b-lactam resistance
To analyse the effect of SA1665 inactivation on
methicillin resistance, nonpolar markerless deletions of
SA1665 (Figure 1B) were constructed in a selection of
clinical MRSA isolates, which varied in their genetic
background, SCCmec type, and mecA regulation [24].
Strain CHE482, belongs to clonal complex CC45 and
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Figure 1
DNA-binding protein purification assay using mec
operator DNA region as a bait.A ,S i l v e rs t a i n e d
SDS-polyacrylamide protein gel containing the elutions from
DNA-binding protein capture assays performed with either
DNA-coated (+) or uncoated (-) streptavidin magnetic
beads. One protein band, indicated by the arrow, was only
captured by the DNA-coated beads, indicating that it bound
specifically to the mec operator DNA. The protein size
marker (M) is shown on the left. B, Organisation of the
genomic region surrounding SA1665. The regions used to
construct the deletion mutants are indicated by lines framed
by inverted arrow, which represent the positions of primers
used for their amplification. The chromosomal organisation,
after deletion of SA1665 is shown beneath. The position of
the SA1665 transcriptional terminator, which remained
intact after SA1665 markerless deletion is indicated (⫯).
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Figure 2
Electromobility shift of mec operator DNA by
SA1665. A, Gel shift using biotinylated DNA (6 ng) and
crude protein extracts. Lane 1, DNA only control; lanes
2 and 3, DNA incubated with 200 ng and 500 ng of crude
protein extract from E. coli BL21 pET28nHis6, respectively;
lanes 4 and 5, DNA incubated with 200 ng and 500 ng of
crude protein extract from E. coli BL21 pME20, expressing
SA1665, respectively. B, Gel shift of biotinylated DNA (6 ng)
with purified SA1665 protein. Lane 1, DNA only control;
lanes 2–7 DNA incubated with 10, 40, 75, 150, 200 and
250 ng protein, respectively; lane 8, DNA incubated with
250 ng of protein in the presence of a 130-fold excess of
unlabelled specific competitor DNA; lane 9, DNA incubated
with 250 ng of protein in the presence of unspecific
competitor (herring sperm) DNA.
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(SCCmecN1 [23]); while strains ZH37 (CC45/ST45) and
ZH73 (CC22/ST22) contain type IV SCCmecs.A l lt h r e eo f
these strains have truncated mecI/mecR1 regulatory loci
but intact BlaI/BlaR1 loci controlling mecA expression.
Strain ZH44 (CCT8/ST8) contained a type A mec
complex (mecI-mecR1-mecA)w i t h i nat y p eI IS C C mec,
and had no b-lactamase locus; so mecA was only under
the control of its cognate regulators MecI/MecR1.
Deletion of SA1665 increased oxacillin resistance in all
mutants compared to their corresponding parent strains,
as demonstrated on oxacillin gradient plates (Figure 3A);
with mutants ΔCHE482 and ΔZH37 approximately
doubling in resistance and ΔZH44 and ΔZH73 expressing
considerably higher resistance. Population analysis resis-
tance profiles of the mutants showed a distinct shift at the
top of the curve, indicating that the higher resistance
was due to increased basal oxacillin resistance levels
(Figure 3B). Strains CHE482/ΔCHE482 and ZH37/
ΔZH37hadverysimilarresistanceprofiles,despitehaving
different SCCmec elements, suggesting that it was their
common clonal background (CC45) that determined
their resistance levels and the extent of resistance increase
upon SA1665 deletion.
Growth curve analyses showed that deletion of SA1665
slightly reduced the growth rate of all strains tested
(Figure 3C). Wild type growth rates were restored upon
complementation (data not shown).
Resistance complementation
Plasmids pME26 and pME27 were constructed for
complementationofthe deletion mutants. Bothplasmids
contained the SA1665 orf along with its own promoter
and transcriptional terminator. Strains ΔCHE482,
ΔZH37, and ΔZH73 were complemented with pME26,
and intrinsically kanamycin resistant strain ΔZH44 was
complemented with pME27. Wild type-like resistance
levels were restored in all mutants by introduction of the
complementing plasmids, as shown by gradient plates
(Figure 3A).
Transcriptional analyses
Primer extension, using the 5'-biotinylated primer me97,
identified two potential SA1665 transcriptional start sites
(TSS), 76-nt and 139-nt upstream of the SA1665 ATG start
codon (Figure 4A). Predicted s
A promoter consensus -10/-
35 box sequences were located upstream of both TSS
(Figure 4B). Identical TSS were also identified using the
downstream primer me98 (data not shown).
Northern blot analysis was used to investigate SA1665
expression and the influence of SA1665 deletion on
mecA and mecR1 transcription. RNA samples taken from
different time points over the growth curve of CHE482
showed that SA1665 was expressed strongly in early
exponential phase at OD600 nm 0.25 and 0.5, then
transcript levels decreased and were almost undetectable
in early stationary phase at OD600 nm 4.0 (Figure 5A). In
addition to the main transcript of ~0.46 kb, a weaker,
larger transcript of ~0.6 kb was also visible, especially at
later growth stages. Figure 5B shows the transcriptional
behaviour of SA1665 when CHE482 cells were
Figure 3
Effect of SA1665 deletion on oxacillin resistance.
A, Growth of MRSA strains and their SA1665 deletion
mutants, containing empty plasmid vector pAW17 or pBUS1,
and trans complemented mutants, containing pME26 or
pME27, was compared on plates containing appropriate
oxacillin gradients, as indicated. Plates were supplemented
with either kanamycin (25 μg/ml) or tetracycline (5 μg/ml) to
ensure plasmid maintainence. B, Representative population
analysis profiles of MRSA strains CHE482, ZH37, ZH44, and
ZH73 and their corresponding mutants. Wildtype strains are
indicated by squares and mutants by triangles. x- and y-axis
show the oxacillin concentrations (μg/ml) and the cfu/ml,
respectively. Oxacillin concentrations used were two-fold
dilutions ranging from 0.1–256 μg/ml for strains CHE482 and
ZH37 and 1–1024 μg/ml for strains ZH44 and ZH73.
C, Growth curves of wildtype strains (solid lines, closed
symbols) and their corresponding SA1665 mutants (dashed
lines, open symbols); CHE482 (diamonds), ZH37 (triangles),
ZH44 (circles), ZH73 (squares).
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TTGTTGACTTGATCAAAATTTAATACAAATGTGAAATTGA
CTCTTTTCATTTTATTAAAAATATATTAAGATGTAATCTG
TGTTTCAAGAAATGTGTATTATTGCAATTTCTTGTGTCCG
GATAAAATTCCCCAAACAGAAAGGTAGATAACAGAATGGA
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Figure 4
Primer extension analysis of SA1665.A ,L a n e sA ,C ,G ,
T show the dideoxy-terminator sequencing ladder and lane
RT the reverse transcription products obtained using primer
me97. Two potential transcriptional start sites (TSS) were
identified, as indicated by arrows (◀). B, Sequence of the
SA1665 promoter region. TSS (+1) are shown in bold,
putative -10 and -35 promoter sequences are underlined, the
predicted ribosome binding site (rbs) is framed and the
translational start (ATG) of SA1665 is highlighted in grey.
Figure 5
Northern and Western blot analyses.A ,T r a n s c r i p t i o n
of SA1665 over growth in CHE482, with RNA harvested at
the OD600 nm values indicated. B, Transcription of SA1665
from CHE482 grown to OD600 nm 0.25 and either left
uninduced (-) or induced with either 4 or 120 μg/ml of
cefoxitin fo 0', 10' and 30'. C, Transcriptional profiles of
SA1664, SA1665, SA1666 and SA1667 in CHE482 and
ΔCHE482, grown to OD600 nm 0.25 and either uninduced or
induced with cefoxitin 4 μg / m lf o r0 ' ,1 0 'o r3 0 ' .
Approximate sizes of transcripts, in kb, are indicated on the
right of the blots. D, Transcription of mecA and mecR1 in
CHE482 and ΔCHE482, grown to OD 0.25 and either left
uninduced or induced with cefoxitin (4 μg/ml) and sampled
after 0', 10' and 30'. Ethidium bromide stained 16S rRNA
bands from all Northern gels are shown as a comparative
indication of RNA loading. E, Western blots showing
amounts of PBP2a in ZH44 and ZH73 and their respective
SA1665 deletion mutants, before (0') and after induction
with 4 μg/ml of cefoxitin for 10' and 30'.
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(120 μg/ml) concentrations of cefoxitin. These results
showed that low levels of cefoxitin, such as those used to
induce mecA/mecR1 transcription, appeared to slightly
decrease SA1665 transcription after 30 min exposure,
while larger, inhibitory concentrations caused even more
significant alterations in the SA1665 transcriptional
profile, making it similar to that normally seen in
stationary phase growth. These results indicate that
transcription of SA1665 may respond in some way to
cell wall stress, rather than in direct response to the
presence of b-lactams. This observation is based on
relatively subtle changes in SA1665 transcription, espe-
cially at low concentrations of cefoxitin such as those
required for mecA/mecR1 induction. Since deletion of
SA1665 has been shown to increase b-lactam resistance,
reduced SA1665 transcription in the presence of b-lac-
tams may also provide some protection against b-lactam
exposure.
Northerns also showed that, as expected, the SA1665
transcripts were absent from the deletion mutant
(Figure 5C), and additional experiments demonstrated
that wild type SA1665 transcription patterns were
restored by complementation of ΔCHE482 with pME26
(data not shown). The effects of SA1665 deletion on
directly up- and down-stream genes were also investi-
gated. Northern blots of the neighbouring genes SA1664,
SA1666 and SA1667, showed that expression of all
three genes was very weak compared to that of SA1665.
Aw e a kt r a n s c r i p to fa b o u t3k bw a sp r e s e n ti n
hybridizations probed with orfs SA1665-SA1667. This
band decreased in size in the SA1665 mutant when
probed with SA1666 and SA1667. One of the transcripts
hybridising to the SA1664 probe also decreased in size
by ~0.5 kb in the SA1665 mutant, suggesting that
SA1665 was present on several transcripts of different
lengths, including a high abundance monocistronic
transcript and low abundance polycistronic transcripts
(Figure 5C). Transcript abundance of both the upstream
SA1666-SA1667 operon and the downstream SA1664-
specific transcript all appeared to increase slightly in
ΔCHE482. The significance of these subtle increases in
transcription are unknown, however, polar effects from
SA1665 deletion seem unlikely, based on the facts that
all genes were still transcribed, their transcription levels
all remained extremely low and the transcriptional
terminator of SA1665 remained intact in the deletion
mutant (Figure 1B).
Expression of mecR1 and mecA were analysed from RNA
of uninduced and induced cultures of CHE482 and
ΔCHE482. Cells were induced at OD600 nm 0.25
(Figure 5D) and 1.0 (data not shown) with sub-
inhibitory concentrations of cefoxitin, to relieve BlaI-
repression of mecA. mecR1, although truncated in
CHE482, was still transcribed and had the same
expression pattern as mecA, as both became derepressed
over time and had the highest transcript levels after 30
m i no fi n d u c t i o n .I nt h em u t a n tΔCHE482, transcripts of
both mecA and mecR1' were unaffected by SA1665
deletion, indicating that SA1665 had no influence on
their expression at either OD 0.25 (Figure 5D) or OD 1.0
(data not shown). SA1665 deletion also had no effect on
mecA transcription or induction in strains ZH37, ZH44
and ZH73 (data not shown).
Western blot analysis
Mutants of CHE482 and of ZH44 and ZH73, which had
the largest differences in oxacillin resistance levels, were
analysed by Western blot analysis to determine if
SA1665 affected production of PBP2a from mecA.A s
shown in Figure 5E, all pairs of wild type and mutant
strains had similar amounts of PBP2a present both
before and after induction with cefoxitin, indicating
that SA1665 deletion did not alter amounts of PBP2a
produced. Therefore it seems that SA1665 exerts no
direct control over mecA or PBP2a expression.
Discussion
Methicillin resistance in MRSA is primarily dependent on
t h ep r e s e n c eo ft h emecA gene, however, resistance levels
are generally governed by strain-specific factors includ-
ing mecA regulatory elements and other chromosomal
fem/aux factors which either enhance or repress the
expression of resistance. For instance, the very low-level
methicillin resistance of the Zurich drug clone CHE482,
was shown to be controlled by its genetic background
[12] suggesting that it either contained or lacked certain
fem/aux factors involved in controlling resistance expres-
s i o n .M a n yo ft h ec u r r e n t l yk n o w nfem/aux factors are
directly or indirectly involved in cell wall synthesis and
turnover, or envelope biogenesis, however there still
remain factors of unknown function. Most of the
currently known fem/aux factors reduce methicillin
resistance levels when inactivated. A few genes, such as
lytH, dlt, norG, sarV and cidA increase resistance levels
upon inactivation or mutation. All of these genes, except
norG, which is an efflux pump regulator, play a role in
either autolysis or are important for cell physiology and
growth [25-30]. Other genes increase b-lactam resistance
upon overexpression, such as hmrA coding for a putative
amidohydrolase, hmrB coding for a putative acyl carrier
protein [31], or the NorG-controlled abcA multidrug
efflux pump [28].
SA1665, a predicted DNA-binding transcriptional reg-
u l a t o r ,w a sf o u n dt ob i n dt oaD N Af r a g m e n tc o n t a i n i n g
the mecA promoter region. However, although this
BMC Microbiology 2009, 9:15 http://www.biomedcentral.com/1471-2180/9/15
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did not appear to directly control mecA or mecR1
transcription or PBP2a production. Therefore its binding
to the mecA region may have no specific regulatory
function. Such interactions have been noted before, such
as the HTH protein NorG, which was shown to bind
specifically to norA, norB and norC promoters, but only
transcription of norB was increased when NorG was
overexpressed [28]. We have to postulate therefore that
SA1665 may modulate b-lactam resistance in a mecA-
independent manner, by controlling cellular functions
affecting resistance levels. Experiments to determine the
SA1665 regulon are ongoing. The impact of deleting
SA1665 in MRSA was extremely strain specific, under-
lining the importance of the genetic background in
governing the final methicillin resistance levels of MRSA,
and demonstrating the large genomic variability between
different strain lineages.
Conclusion
SA1665 is a previously uncharacterised DNA-binding
protein that has a negative effect on b-lactam resistance
in MRSA. The SA1665 protein was identified in a DNA-
binding protein purification assay, in which it bound
to a DNA fragment covering the mec operator region.
However, while nonpolar deletion of SA1665 was
shown to increase oxacillin resistance levels in several
heterogeneously resistant MRSA, its deletion had no
effect on mecA transcription or PBP2a production.
Therefore the negative impact of SA1665 on methicillin
resistance is most likely to be through the regulation of
other chromosomal factors or cellular functions required
for methicllin resistance.
Methods
Strains and growth conditions
Strains and plasmids used in this study are listed in
Table 1. Clinical isolates are from the IMM collection in
Zurich, Switzerland. Strains were grown at 37°C in Luria
Bertani (LB) broth, shaking at 180 rpm, or on LB agar.
Media were supplemented with the following antibiotics
when appropriate: 25 or 50 μg/ml kanamycin, 10 μg/ml
chloramphenicol, 5 or 10 μg/ml tetracycline, 100 μg/ml
ampicillin. Concentrations of cefoxitin used for transcrip-
tional induction were either sub-inhibitory (4 μg/ml) or
inhibitory (120 μg/ml).
Susceptibility testing
Oxacillin resistance levels were compared by swabbing
0.5 McFarland cell suspensions across agar plates
containing appropriate concentration gradients of oxa-
cillin. For population analysis profiles, appropriate
dilutions of an overnight culture, ranging from 10
0 to
10
8, were plated on increasing concentrations of
oxacillin. Plates were incubated at 35°C and colony
forming units per ml (cfu/ml) were determined after
48 h.
Table 1: Strains and plasmids used in this study
Strain/plasmid Relevant genotype
a Reference/source
S. aureus
CHE482 clinical MRSA isolate, CC45/ST45, SCCmecN1, blaZ (pBla) [23, 24]
ΔCHE482 CHE482 ΔSA1665 this study
ZH37 clinical MRSA isolate, CC45/ST45, SCCmec type IV, blaZ [24]
ΔZH37 ZH37 ΔSA1665 this study
ZH44 clinical MRSA isolate, CCT8/ST8, SCCmec type II, aac-aph [24]
ΔZH44 ZH44 ΔSA1665 this study
ZH73 clinical MRSA isolate, CC22/ST22, SCCmec type IV, blaZ [24]
ΔZH73 ZH73 ΔSA1665 this study
RN4220 NCTC8325-4, restriction negative [38]
E. coli
DH5a restriction-negative strain for cloning Invitrogen
BL21 (DE3) F
- ompT hsdSB(rB
-mB
-) gal dcm (DE3) Novagen
Plasmids
pBUS1 S. aureus-E. coli shuttle vector, tetL [37]
pAW17 S. aureus-E. coli shuttle vector, aac-aph [37]
pKOR1 S. aureus-E. coli shuttle vector, cat, bla [34]
pME17 pKOR1-SA1664/SA1666, cat this study
pET28nHis6 E. coli protein expression vector, with n-terminal His6 tag, aac-aph D. Frey, unpublished
pME20 pET28nHis6-SA1665, aac-aph this study
pME26 pAW17-SA1665 and 700 bp up- and 380 down-stream, aac-aph this study
pME27 pBUS1-SA1665 and 700 bp up- and 380 bp down-stream, tetL this study
aAbbreviations: CC, clonal complex; ST, sequence type.
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Crude protein extracts were isolated from CHE482,
grown under normal culture conditions until OD600 nm
1.5. Cells were harvested, resuspended in PBS (pH 7.4)
a n dm e c h a n i c a l l yl y s e du s i n gL y s i n gM a t r i xB( B I O1 0 1
Systems) tubes and a FastPrep FP120 (BIO 101 Systems).
Suspensions were clarified by centrifugation and super-
natants, containing soluble cytoplasmic proteins, were
transferred to Amicon Ultra centrifugal filter devices
(Millipore) with a pore cut-off size of 10 kDa. Proteins
were then washed and concentrated in 1× binding buffer
( 1 0m MT r i s - H C l ,p H7 . 5 ,1m ME D T A ,a n d1m MD T T ,
0.5 M NaCl). Protein concentrations were measured by
Bradford assay (BioRad Laboratories GmbH) [32].
Primer pair me36F/me36Rbiot (Table 2) were used to
amplify a biotinylated mecA promoter/operator frag-
ment, which was bound to streptavidin coated magnetic
beads (Dynabeads M-280 Streptavidin, DYNAL BIO-
TECH) according to the manufacturer's instructions.
Binding reactions, containing DNA-coated beads mixed
with 100 μg of crude protein extract in 1× protein
binding buffer (20 mM Hepes, pH 7.6, 1 mM EDTA,
10 mM (NH4)2SO4, 1 mM DTT, 0.2% Tween 20 (w/v),
30 mM KCl), 0.02 μg/μl poly d(I-C) and 2 ng/μl poly
L-lysine, were incubated at room temperature for 30 min
with constant rotation. Beads were then washed and
binding-proteins eluted in elution buffer (1× protein
binding buffer containing 2 M KCl). Eluted proteins
were dialysed against water, concentrated by evapora-
tion, and run on 15% SDS polyacrylamide gels. Gels
were silver stained using the Protein Silver Staining kit
(Amersham Biosciences AB) without the addition of
glutaraldehyde. Protein bands were excised from gels
and analysed by mass spectrometry (LC/ESI/MS/MS) at
the Functional Genomics Centre, Zurich. The SA1665
protein sequence [BAB42933] was analysed by Blast
search http://www.ncbi.nlm.nih.gov/BLAST and motif
scan http://myhits.isb-sib.ch/cgi-bin/motif_scan.
Expression of recombinant SA1665 protein
SA1665 was amplified using primer pair me65BamHI/
me65XhoI (Table 2) and cloned in-frame into
Table 2: Oligonucleotide primers used in this study.
Primer name Nucleotide sequence (5'-3')
a Reference
Markerless deletion construction
me62attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACTGGCT-
TATTCGCTTGA
This study
me51BamHI ATTAGGATCCTTAGTACATATCTAGGCCTA This study
me62BamHI ATTAGGATCCACTCTGTCTATCCATTCTGT This study
me62attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTTGTGCGACAAG-
GATTGCGA
This study
Cloning
me94BamHI ATTAGGATCCTCTTCAATCACTTGGCCAAT This study
me94Asp718 ATTAGGTACCAAGGTGCTGATGGTTATGAA This study
me65BamHI ATTAGGATCCGATAGACAGAGTTTTACAGA This study
me65XhoI ATTACTCGAGGATATGTACTAATTCTTCTT This study
Protein-DNA binding and EMSA
me36F TGATAACACCTTCTACACCT This study
me36Rbiot BIOT-AACCCGACAACTACAACTAT This study
me36R AACCCGACAACTACAACTAT This study
Primer extension
me97 BIOT-ACTCTGTCTATCCATTCTGT This study
me98 BIOT-CAGCCTCTATACGAACCATT This study
me52F CCACTGGCTTATTCGCTTGA This study
me52R TGTGCGACAAGGATTGCGAT This study
Gene/transcript detection
mecAP4 TCCAGATTACAACTTCACCAGG [42]
mecAP7 CCACTTCATATCTTGTAACG [42]
SA1665F TTCGTATAGAGGCTGGTTAG This study
SA1665R AATTGGTTGGTTATCTGGAT This study
mecR1F TGACACGACTTCTTCGGTTA This study
mecR1R AACGTATATGTTCATGGCGA This study
SA1664F TCAGCATGTAGATAACGCAA This study
SA1664R ATGTCACAATTGTTCTTGCT This study
SA1666F GACCATTATATTGTGCGACA This study
SA1666R TTGTGCCTTAGGATGTATCA This study
SA1667F TTGTGCCTTAGGATGTATCA This study
SA1667R TAATACCGTGTGATGAAGCT This study
aRestriction sites are underlined; BIOT: end-labelled with biotin.
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plasmid, pME20, was transformed into E. coli BL21 for
expression of recombinant nHis6-SA1665 protein. To
maximise the abundance of soluble protein produced,
cultures were grown in osmotic shock medium at 37°C
(1 g/l NaCl, 16 g/l tryptone, 10 g/l yeast, 1 M sorbitol, 10
mM betaine, modified from [33]) to an OD600 nm of 0.5,
cooled briefly on ice, then induced by adding 100 μM
IPTG and growing overnight at 22°C. Crude soluble
proteins were extracted using CelLyticB 2× cell lysis
reagent (SIGMA). HIS-Select Cobalt Affinity Gel
(SIGMA) was used to purify recombinant nHis6-
SA1665 according to the manufacturer's instructions.
Electro mobility shift assay
For gel shift assays, 6 ng aliquots of the biotinylated-
DNA fragment used for binding-protein purification
were incubated with 0–250 ng of purified nHis6-SA1665
protein in 1× binding buffer (20 mM Hepes pH 7.6, 1
mM EDTA, 10 mM (NH4)2SO4, 1 mM DTT, 0.2% Tween
20 (w/v), 30 mM KCl) containing 0.05 μg/μlp o l yd ( I - C )
(Roche) and 5 ng/μl poly L-lysine (Roche). For control
binding reactions, 130 × unlabelled mec operator DNA
(amplified using primers me36F/me36R, Table 2) was
used as a specific binding competitor and 6 ng of herring
s p e r mD N Aw a su s e da su n s p e c i f i cc o m p e t i t o rD N A .
Binding was carried out at 22°C for 30 min. Samples
were run on 6% native polyacrylamide gels, contact
blotted onto positively charged nylon membrane and
detected with the Biotin Chromogenic Detection Kit
(Fermentas).
Primer extension
RNA was extracted from CHE482 cultures that were
grown to OD600 nm 0.5, as previously described [12].
Primer extension reactions were performed using 20 μg
of total RNA and 3 pmol of the 5'-biotin-labelled
primers me97 and me98 (Table 2) using Superscript II
reverse transcriptase (Invitrogen), according to the
manufacturers instructions. Sequencing reactions were
performed using the Thermo Sequenase cycle sequencing
kit (U.S. Biochemicals). The Biotin Chromogenic Detec-
tion Kit (Fermentas) was used for biotin detection.
Markerless deletion of SA1665
In frame markerless deletions of SA1665, from the
chromosomes of CHE482, ZH37, ZH44, and ZH73,
were constructed using the pKOR1 allelic replacement
system,asdescribedbyBae etal.[34].Primerpairsusedto
amplify the DNA fragments flanking SA1665, for recom-
bination into pKOR1 were: me62attB1/me51BamHI and
me62BamHI/me62attB2 (Table 2). All deletion mutants
were confirmed by nucleotide sequencing over the
deleted region, as well as by Southern blot analysis [35]
and pulsed field gel electrophoresis (PFGE) [36].
Cloning of SA1665 for complementation
A 1533-bp DNA fragment, containing SA1665 together
with 690-bp of upstream and 379-bp of downstream
DNA, was amplified from strain CHE482 using primers
me94BamHI/me94Asp718 (Table 2) and cloned into the
E. coli/S. aureus shuttle vectors pAW17 and pBUS1 [37],
creating the complementing plasmids pME26 and
pME27, respectively. Plasmids were electroporated into
RN4220 [38] and then transduced into different strains
using phage 80a.
Northern blot analysis
Strains were grown overnight in LB (Difco), diluted
1:200 and grown for another 3 h. This preculture was
used to inoculate 150 ml (1:1000) of fresh prewarmed
LB. Cells were then grown to OD600 nm 0.25 or 1.0 and
either left uninduced or induced with cefoxitin 4 or 120
μg/ml. Cultures were sampled from both uninduced and
induced cells at time point 0' before induction and at 10'
and 30' (min) after induction. To monitor SA1665
expression over growth, separate cultures were also
sampled at different growth stages corresponding to
OD600 nm 0 . 2 5 ,0 . 5 ,1 ,2 ,a n d4 .T o t a lR N Aw a se x t r a c t e d
as described by Cheung et al. [39]. RNA samples (10 μg)
were separated in a 1.5% agarose-20 mM guanidine
thiocyanate gel in 1× TBE running buffer [40], then
transferred and detected as described previously [41].
Digoxigenin (DIG) labelled-probes were amplified
using the PCR DIG Probe synthesis kit (Roche).
T a b l e2c o n t a i n st h el i s to fp r i m e rp a i r su s e df o rt h e
amplification of SA1664, SA1665, SA1666, SA1667,
mecR1 and mecA [42] probes. All Northern's were
repeated at least two times, using independently isolated
RNA samples.
Western blot analysis
Cells were cultured, as described for Northern blot
analysis, to OD600 nm 1.0, then induced with cefoxitin
4 μg/ml. Samples were collected at time 0 (before
induction), 10 and 30 min (after induction). Cells were
harvested by centrifugation, resuspended in PBS pH 7.4
containing DNase, lysostaphin and lysozyme (150 μg/ml
of each) and incubated for 1 h at 37°C. Suspensions
were then sonicated and protein aliquots (15 μg) were
separated on 7.5% SDS-polyacrylamide gels, blotted
onto nitrocellulose membranes (Hybond) and stained
with Ponceau to confirm equal protein loading. PBP2a
detection was performed using monoclonal PBP2a
antibody (1:20000) from the MRSA-screen kit (Denka
Seiken).
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